Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright Future

Overview

Journal Diabetes

Specialty Endocrinology

Date 2024 Oct 24

PMID 39446565

Authors

Roberto Mallone

Emily Sims

Peter Achenbach

Chantal Mathieu

Alberto Pugliese

Mark Atkinson

Sanjoy Dutta

Carmella Evans-Molina

David Klatzmann

Anne Koralova

S Alice Long

Lut Overbergh

Teresa Rodriguez-Calvo

Anette-Gabriele Ziegler

Sylvaine You

Affiliations

Soon will be listed here.

Abstract

Article Highlights:

References

Greenbaum C, Beam C, Boulware D, Gitelman S, Gottlieb P, Herold K . Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012; 61(8):2066-73. PMC: 3402330. DOI: 10.2337/db11-1538. View

Bogun M, Bundy B, Goland R, Greenbaum C . C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet. Diabetes Care. 2020; 43(8):1836-1842. PMC: 7372058. DOI: 10.2337/dc19-2288. View

Leete P, Oram R, McDonald T, Shields B, Ziller C, Hattersley A . Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia. 2020; 63(6):1258-1267. PMC: 7228905. DOI: 10.1007/s00125-020-05115-6. View

Tatovic D, Marwaha A, Taylor P, Hanna S, Carter K, Cheung W . Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nat Med. 2024; 30(9):2657-2666. PMC: 11405276. DOI: 10.1038/s41591-024-03115-2. View

Leete P, Willcox A, Krogvold L, Dahl-Jorgensen K, Foulis A, Richardson S . Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and the Age at Onset of Type 1 Diabetes. Diabetes. 2016; 65(5):1362-9. DOI: 10.2337/db15-1615. View

Phillip M, Achenbach P, Addala A, Albanese-ONeill A, Battelino T, Bell K . Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024; 67(9):1731-1759. PMC: 11410955. DOI: 10.1007/s00125-024-06205-5. View

Rigby M, Harris K, Pinckney A, DiMeglio L, Rendell M, Felner E . Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015; 125(8):3285-96. PMC: 4623571. DOI: 10.1172/JCI81722. View

Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View

Waibel M, Thomas H, Wentworth J, Couper J, MacIsaac R, Cameron F . Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial. Trials. 2022; 23(1):433. PMC: 9125350. DOI: 10.1186/s13063-022-06356-z. View

10.

Colli M, Hill J, Marroqui L, Chaffey J, Dos Santos R, Leete P . PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction. EBioMedicine. 2018; 36:367-375. PMC: 6197434. DOI: 10.1016/j.ebiom.2018.09.040. View

11.

Rubio-Navarro A, Gomez-Banoy N, Stoll L, Dundar F, Mawla A, Ma L . A beta cell subset with enhanced insulin secretion and glucose metabolism is reduced in type 2 diabetes. Nat Cell Biol. 2023; 25(4):565-578. PMC: 10449536. DOI: 10.1038/s41556-023-01103-1. View

12.

Ziegler A, Rewers M, Simell O, Simell T, Lempainen J, Steck A . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309(23):2473-9. PMC: 4878912. DOI: 10.1001/jama.2013.6285. View

13.

Eisenbarth G . Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986; 314(21):1360-8. DOI: 10.1056/NEJM198605223142106. View

14.

Leslie R, Ma R, Franks P, Nadeau K, Pearson E, Redondo M . Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes. Lancet Diabetes Endocrinol. 2023; 11(11):848-860. DOI: 10.1016/S2213-8587(23)00159-6. View

15.

Hagopian W, Ferry Jr R, Sherry N, Carlin D, Bonvini E, Johnson S . Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013; 62(11):3901-8. PMC: 3806608. DOI: 10.2337/db13-0236. View

16.

Marcovecchio M, Hendriks A, Delfin C, Battelino T, Danne T, Evans M . The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia. 2024; 67(6):995-1008. PMC: 11058619. DOI: 10.1007/s00125-024-06124-5. View

17.

von Herrath M, Bain S, Bode B, Clausen J, Coppieters K, Gaysina L . Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021; 9(4):212-224. DOI: 10.1016/S2213-8587(21)00019-X. View

18.

Xhonneux L, Knight O, Lernmark A, Bonifacio E, Hagopian W, Rewers M . Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression. Sci Transl Med. 2021; 13(587). PMC: 8447843. DOI: 10.1126/scitranslmed.abd5666. View

19.

Atkinson M, Eisenbarth G, Michels A . Type 1 diabetes. Lancet. 2013; 383(9911):69-82. PMC: 4380133. DOI: 10.1016/S0140-6736(13)60591-7. View

20.

Skyler J, Krischer J, Wolfsdorf J, Cowie C, Palmer J, Greenbaum C . Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28(5):1068-76. DOI: 10.2337/diacare.28.5.1068. View